Novo Nordisk and Eli Lilly ramped up lobbying efforts when US legislators targeted insulin prices

When legislators began seriously thinking about insulin prices in the US, Novo Nordisk and Eli Lilly responded by increasing their lobbying contributions.
Photo: Novo Nordisk & Ritzau Scanpix/Reuters/Vincent Kessler
Photo: Novo Nordisk & Ritzau Scanpix/Reuters/Vincent Kessler
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen

In 2021, when work began on legislation pertaining to the insulin prices in the US, Novo Nordisk and US-based Eli Lilly intensified their lobbying efforts, as reported by media Stat.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading